Home›Research›Compare›GLP-1 (7-37) vs Tirzepatide
Peptide ComparisonGLP-1 (7-37) vs Tirzepatide
Both are Metabolic peptides.
GLP-1 (7-37)
GLP-1 fragment
33 providers listed
Tirzepatide
Dual GLP-1
Half-life: ~5 days (once-weekly dosing)
541 providers listed
Tirzepatide is FDA-approved, while GLP-1 (7-37) is not evaluated — the clearest structural difference between them.
GLP-1 (7-37)
Half-life
—
Tirzepatide
Half-life
~5 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Tirzepatide |
| Further along in FDA review | Tirzepatide |
| More provider options (33 vs 541) | Tirzepatide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
GLP-1 (7-37)
Tirzepatide
Tirzepatide
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Tirzepatide Once Weekly for the Treatment of Obesity
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospectiv…
+5 more
About GLP-1 (7-37)
Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.
About Tirzepatide
Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation adds a complementary mechanism to GLP-1 agonism — enhancing insulin secretion, reducing glucagon, and modulating adipose tissue metabolism independently of GLP-1 pathways. The combination produces greater average weight reduction in clinical trials than selective GLP-1 agonists at comparable doses.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
GLP-1 (7-37)
Class-based (investigational)
Tirzepatide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Where to source these peptides
GLP-1 (7-37)
33 listed
Browse directory →
Providers offeringTirzepatide
541 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.